Horizon Pharma plc Named to the Crain’s Chicago Business 2017 “Best Places To Work” List
April 07, 2017 08:00 ET
|
Horizon Pharma plc
DUBLIN, Ireland, April 07, 2017 (GLOBE NEWSWIRE) -- Horizon Pharma plc (NASDAQ:HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and...
Horizon Pharma plc Announces the U.S. Patent and Trademark Office Issuance of an Additional Notice of Allowance With Claims Covering VIMOVO® (naproxen/esomeprazole) Delayed Release Tablets
March 30, 2017 07:00 ET
|
Horizon Pharma plc
DUBLIN, Ireland, March 30, 2017 (GLOBE NEWSWIRE) -- Horizon Pharma plc (NASDAQ:HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and...
Horizon Pharma plc to Present Data on RAVICTI® (glycerol phenylbutyrate) Oral Liquid for Urea Cycle Disorder Patients Aged Two Months to Two Years
March 22, 2017 09:00 ET
|
Horizon Pharma plc
DUBLIN, Ireland, March 22, 2017 (GLOBE NEWSWIRE) -- Horizon Pharma plc (NASDAQ:HZNP), a biopharmaceutical company focused on improving patients’ lives by identifying, developing, acquiring and...
Horizon Pharma plc Announces "UCD in Common" for the Urea Cycle Disorder (UCD) Community
March 16, 2017 09:30 ET
|
Horizon Pharma plc
DUBLIN, Ireland, March 16, 2017 (GLOBE NEWSWIRE) -- Horizon Pharma plc (NASDAQ:HZNP), a biopharmaceutical company focused on improving patients’ lives by identifying, developing, acquiring and...
Horizon Pharma plc Announces Urea Cycle Disorders Medical Foods and Supplements Financial Assistance Program
March 02, 2017 08:00 ET
|
Horizon Pharma plc
DUBLIN, Ireland, March 02, 2017 (GLOBE NEWSWIRE) -- Horizon Pharma plc (NASDAQ:HZNP), a biopharmaceutical company focused on improving patients’ lives by identifying, developing, acquiring and...
Horizon Pharma plc Launches RAREis™ Campaign Elevating Faces of the Rare Disease Community
February 28, 2017 08:00 ET
|
Horizon Pharma plc
DUBLIN, Ireland, Feb. 28, 2017 (GLOBE NEWSWIRE) -- Horizon Pharma plc (NASDAQ:HZNP), a biopharmaceutical company focused on improving patients’ lives by identifying, developing, acquiring and...
Horizon Pharma plc Announces Fourth-Quarter and Full-Year 2016 Financial Results and Provides Full-Year 2017 Net Sales and Adjusted EBITDA Guidance
February 27, 2017 07:00 ET
|
Horizon Pharma plc
-- Fourth-Quarter 2016 Net Sales of $310.3 Million; Up 27 Percent ---- Fourth-Quarter 2016 Net Loss of $130.5 Million(1); Adjusted EBITDA of $136.4 Million -- -- Fourth-Quarter 2016 Operating Cash...
Horizon Pharma plc to Participate in Cowen and Company 37th Annual Health Care Conference
February 14, 2017 08:00 ET
|
Horizon Pharma plc
DUBLIN, Ireland, Feb. 14, 2017 (GLOBE NEWSWIRE) -- Horizon Pharma plc (Nasdaq:HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and...
Horizon Pharma plc to Host Fourth-Quarter 2016 Conference Call and Webcast on February 27, 2017
January 27, 2017 08:00 ET
|
Horizon Pharma plc
DUBLIN, Ireland, Jan. 27, 2017 (GLOBE NEWSWIRE) -- Horizon Pharma plc (Nasdaq:HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and...
Horizon Pharma plc Announces the U.S. Patent and Trademark Office Issuance of an Additional Notice of Allowance With Claims Covering RAVICTI® (glycerol phenylbutyrate) Oral Liquid
December 22, 2016 16:05 ET
|
Horizon Pharma plc
DUBLIN, Ireland, Dec. 22, 2016 (GLOBE NEWSWIRE) -- Horizon Pharma plc (NASDAQ:HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and...